Market closed
Veru/$VERU
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Veru
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.
Ticker
$VERU
Sector
Trading on
Industry
Personal Care Products
Headquarters
Employees
189
Website
Veru Metrics
BasicAdvanced
$96M
Market cap
-
P/E ratio
-$0.31
EPS
-0.43
Beta
-
Dividend rate
Price and volume
Market cap
$96M
Beta
-0.43
52-week high
$1.92
52-week low
$0.36
Average daily volume
848K
Financial strength
Current ratio
3.623
Quick ratio
2.9
Long term debt to equity
30.972
Total debt to equity
33.594
Interest coverage (TTM)
-101.29%
Management effectiveness
Return on assets (TTM)
-38.35%
Return on equity (TTM)
-126.72%
Valuation
Price to revenue (TTM)
5.65
Price to book
2.56
Price to tangible book (TTM)
3.14
Price to free cash flow (TTM)
-2.936
Growth
Revenue change (TTM)
-6.20%
Earnings per share change (TTM)
-79.78%
3-year revenue growth (CAGR)
-37.37%
3-year earnings per share growth (CAGR)
441.66%
What the Analysts think about Veru
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Veru stock.
Veru Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Veru Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Veru News
AllArticlesVideos
Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek
GlobeNewsWire·1 week ago
Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss
GlobeNewsWire·3 weeks ago
Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Veru stock?
Veru (VERU) has a market cap of $96M as of November 13, 2024.
What is the P/E ratio for Veru stock?
The price to earnings (P/E) ratio for Veru (VERU) stock is 0 as of November 13, 2024.
Does Veru stock pay dividends?
No, Veru (VERU) stock does not pay dividends to its shareholders as of November 13, 2024.
When is the next Veru dividend payment date?
Veru (VERU) stock does not pay dividends to its shareholders.
What is the beta indicator for Veru?
Veru (VERU) has a beta rating of -0.43. This means that it has an inverse relation to market volatility.